Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

The Principles and Practice of Cancer Precision Prevention Studies

  • Date: Tuesday, November 12, 2024
  • Time: 11:00am EST to 12:00pm EST

Speaker

Sarah Blagden, M.D., Ph.D.
Department of Oncology
Medical Sciences Division
University of Oxford

Sarah Blagden is a clinician-scientist (M.D., Ph.D.) at the University of Oxford with a more than 20-year established track record of clinical and laboratory research. She is a board-certified medical oncologist having conducted her specialty training at the University of Cambridge and Royal Marsden Hospitals. From 2006-2015, she was director of early-phase trials at Imperial College London and, from 2017 to 2021, director of the Early Phase Clinical Trials Unit at the University of Oxford. She has considerable experience in designing clinical trials, developing methodologies such as complex innovative designs and considering their regulatory aspects. She has conducted numerous early- and late-phase trials as co-investigator, principal, and chief investor. Sarah is now director of Oxford University’s Oncology Clinical Trials Office (OCTO), which is the UK’s first unit to specialize in Precision-Prevention and Early Detection (PPED) studies. In addition, she leads an RNA biology lab exploring post-transcriptional mechanisms of gene regulation in tumorigenesis. She is a member of CRUK’s Prevention and Population Research Committee.

In this seminar, Sarah describes the OCTO experience of developing a pipeline of precision prevention trials, the principles upon which these trials are based, and the practical challenges they have faced so far.